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Chlamydia Serine Protease 
Inhibitor, targeting HtrA, as a New 
Treatment for Koala Chlamydia 
infection
Amba Lawrence1, Tamieka Fraser2, Amber Gillett3, Joel D. A. Tyndall4, Peter Timms2, 
Adam Polkinghorne2 & Wilhelmina M. Huston1,5
The koala, an iconic marsupial native to Australia, is a threatened species in many parts of the country. 
One major factor in the decline is disease caused by infection with Chlamydia. Current therapeutic 
strategies to treat chlamydiosis in the koala are limited. This study examines the effectiveness of an 
inhibitor, JO146, which targets the HtrA serine protease for treatment of C. pecorum and C. pneumoniae 
in vitro and ex vivo with the aim of developing a novel therapeutic for koala Chlamydia infections. Clinical 
isolates from koalas were examined for their susceptibility to JO146. In vitro studies demonstrated 
that treatment with JO146 during the mid-replicative phase of C. pecorum or C. pneumoniae infections 
resulted in a significant loss of infectious progeny. Ex vivo primary koala tissue cultures were used to 
demonstrate the efficacy of JO146 and the non-toxic nature of this compound on peripheral blood 
mononuclear cells and primary cell lines established from koala tissues collected at necropsy. Our results 
suggest that inhibition of the serine protease HtrA could be a novel treatment strategy for chlamydiosis 
in koalas.
Despite the growing recognition of their plight, population numbers of Australia’s iconic native marsupial species, 
the koala (Phascolarctos cinereus), continue to decline in large parts of eastern Australia. Population numbers are 
in decline due to loss of habitat1, motor vehicle trauma2 and domestic dog attacks3. Infectious diseases also place 
a serious burden on this marsupial. The most clinically significant cause of infectious disease in the koala is the 
obligate intracellular bacterial parasite, Chlamydia (Reviewed in Polkinghorne et al.4). Two species are known 
to infect koalas, Chlamydia pecorum and Chlamydia pneumoniae, with the former being the more pathogenic5. 
C. pecorum presents as ocular disease, including discharge, conjunctival and corneal inflammation6; or urogenital 
tract disease, including cystitis, urinary incontinence (termed colloquially as ‘wet bottom’) and fibrosis which can 
cause infertility7. However, the koala C. pecorum infection outcome does not always appear to result in pathol-
ogy as population studies have also shown high chlamydial infection loads in the absence of significant overt 
disease8,9. The clinical manifestations of C. pneumoniae include a range of severe respiratory signs including 
difficulty in breathing, sneezing and coughing, and purulent nasal discharge10.
Koalas are specialized Eucalyptus herbivores who exhibit unique physiological, reproductive and dietary char-
acteristics, including the ability to ingest and metabolize toxic plant metabolites such as phenolic compounds 
and terpenes11. Their unusual metabolism results in limited efficacy of antibiotic treatment, as their efficient 
hepatic metabolism has been proposed to increase the rate of elimination of some therapeutic drugs12. Antibiotic 
treatments commonly used in humans (such as the tetracycline and macrolide antibiotics) cause emaciation in 
koalas and typically result in ineffective clearance of chlamydial infections of the lower genital tract13,14. Currently 
the most effective and commonly used, systemically administered, chlamydial antibiotic therapy for koalas with 
urinary-genital tract infections7,15 is Chloramphenicol 150, (Ceva Delvet, Seven Hill, Australia). This antibiotic 
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has been observed clinically have little detrimental effects on the koala’s specialized gut microflora compared to 
other medications. When administered at a dose rate of 60 mg/kg once each day for 45 days, this product results 
in cessation of shedding of Chlamydia within two weeks of treatment13. However, production of this product is 
limited, and recent shortages and sporadic manufacturing have resulted in the inability to treat some animals 
presenting to animal hospitals with chlamydial infections, with many requiring euthanasia as a consequence of 
disease progression (Personal Communication, Claude Lacasse, Veterinary Services Manager, Australian Wildlife 
Hospital).
All chlamydiae share a developmental cycle that consists of transitions between two main cell types, the infec-
tious non-dividing extracellular form, known as the elementary body (EB), and an intracellular replicative form, 
called the reticulate body (RB)16,17. EBs are responsible for dissemination of infection by attaching to and invad-
ing susceptible cells. Upon infection, EBs are internalized in membrane bound vacuoles termed inclusions. EBs 
differentiate into RBs, the metabolically active form that repeatedly replicate before differentiating back to the 
infectious EB form. The host cell then lyses, releasing EBs that infect neighbouring cells. If this developmental 
cycle is disrupted under stressful growth conditions, such as immunological responses, antibiotics or nutrient 
deprivation, a long term growth that consists of aberrant RB’s that neither replicate, nor differentiate into EBs can 
result in a process termed persistence (reviewed in Abdelrahman & Belland17).
High temperature requirement A (HtrA), is a serine protease, which has been demonstrated to be critical for 
virulence and intracellular survival of many bacteria18–20. We recently demonstrated that C. trachomatis HtrA 
(CtHtrA) is essential for the replicative phase of this organism21. Utilising a screening strategy, we identified a 
serine protease inhibitor (JO146) that binds to HtrA and inhibits the protease activity21. The addition of JO146 
to the mid-replicative phase of the C. trachomatis developmental cycle was lethal in vitro and no obvious toxicity 
was detected in mouse or human cells. The compound was also found to be effective against C. trachomatis in a 
broad range of host cell types21. Similar results for JO146 were also obtained for several other species in the genus 
Chlamydia21. In this study, we provide the basis for a novel therapeutic strategy for the treatment of chlamydiosis 
in koalas using the HtrA protease inhibitor, JO146. Our results suggest that this could be an effective target and 
that further optimization of JO146 could provide valuable new drugs for use in treating the koala.
Results
Characterization of the in vitro growth characteristics of koala C. pecorum urogenital and ocular 
isolates. Our previous work suggested that JO146 was most efficacious when added during the mid-rep-
licative growth phase of C. trachomatis22. However, there are no published growth curves for koala Chlamydia 
isolates so we first needed to profile the growth of these isolates in order to subsequently evaluate inhibitor activ-
ity. Growth curves were conducted for urogenital isolates C. pecorum MarsBar and C. pecorum DBDeUG, and 
ocular isolate C. pecorum IPTaLE23. Formation of infectious units were measured at 20, 28, 36, 44, 52 and 60 h 
PI for C. pecorum MarsBar and C. pecorum IPTaLE (Fig. 1), and a selection of these time points were used for 
C. pecorum DBDeUG for confirmation of growth similarities for urogenital strains (Supplementary Fig. S1). 
All isolates demonstrated characteristic bi-phasic chlamydial growth patterns with infectious elementary body 
(EB) production not detected until 20 h PI and these reached a peak at 36 h PI (Fig. 1). Approximately one-log 
difference was observed between C. pecorum MarsBar and C. pecorum IPTaLE EB yield, when measured at 52 h 
PI (2.85 × 107 IFU/ml and 7.32 × 106 IFU/ml, respectively). The two urogenital isolates C. pecorum IPTaLE and 
C. pecorum DBDeUG were consistent in terms of EB yield at 52 h PI (7.32 × 106 IFU/ml and 3.46 × 106 IFU/ml, 
respectively) (C. pecorum DBDeUG data shown in Supplementary Fig. S1).
The Chlamydia occupy a unique intracellular vacuole termed the inclusion vacuole. The morphology of this 
vacuole was analysed by confocal microscopy on immuno-labelled cultures at selected time points during the 
growth curve. Both urogenital strains showed similar inclusion formation and shape (Fig. 2). Initially, inclusions 
were small and round, located next to the nucleus and increased substantially in size by 36 h PI. Multiple inclu-
sions within a single cell were observed for both strains (Fig. 2). Inclusions were observed to occupy substantial 
cellular space around the nucleus at 36 h PI onwards. A variety of inclusion morphologies were observed, most 
often crescent shaped, around the host cell nucleus. Similarly the ocular isolate C. pecorum IPTaLE formed small 
round inclusions at 20 h PI with an increase in inclusion size observed between 20 and 36 h PI (Fig. 2).
Figure 1. C. pecorum IPTaLE and C. pecorum MarsBar one step growth curve. C. pecorum IPTaLE and 
C. pecorum MarsBar were harvested at 20, 28, 36, 44, 52 and 60 h PI (as indicated on the x-axis) to measure 
inclusion forming units. Error bars indicate the standard error of the mean obtained from triplicate infected 
wells (MOI 0.3).
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In vitro susceptibility testing of koala C. pecorum and C. pneumoniae isolates to chloramphenicol 
and tetracycline. We measured the in vitro susceptibility of koala C. pecorum and C. pneumoniae isolates 
to chloramphenicol and tetracycline. The MICs of tetracycline and chloramphenicol were comparable for both 
koala C. pecorum and C. pneumoniae isolates, with all isolates being susceptible to ≤ 0.25 μ g/ml tetracycline and 
≤ 1.00 μ g/ml chloramphenicol (Table 1). Both antibiotics were chlamydicidal for all isolates at their determined 
MIC values were all within one two-fold dilution across all isolates tested (Table 1).
JO146 addition during the replicative phase of the Chlamydia developmental cycle results in 
significant loss of infectious progeny. As described previously, JO146 is effective in the mid-replicative 
phase of the Chlamydia developmental cycle21. Mid-replicative phase for the C. pecorum isolates was demonstrated 
to be 16 h PI (see Fig. 1). This was estimated based on the observed peak in EB production at approximately 36 h. 
Mid-replicative phase for the C. pneumoniae LPCoLN was determined from data previously published24. Infectious 
progeny (or inclusion forming units; IFU/ml) was determined by passaging the cultures at completion of the 
developmental cycle after treatment. As shown in Fig. 3, JO146 treatment resulted in complete or highly significant 
(p < 0.0001) loss (up to 103–4 log) of progeny (IFU) when added during the replicative phase. In addition, there 
was a considerable amount of variability in susceptibility of the isolates at higher doses of JO146. For example, 
C. pecorum MarsBar had 102 IFU/ml at 150 μ m JO146, while a similarly urogenital clinical isolate C. pecorum AWH4 
had a 105 IFU/ml at 150 μ m. The activity was most effective at higher doses, with 150 μ M being lethal to C. pecorum 
AWH7 (Fig. 3A), C. pecorum PM15 (Fig. 3B), and C. pneumoniae LPCoLN (Fig. 3C).
Figure 2. C. pecorum inclusion vacuole size shows similar morphology among isolates from different 
anatomical sites. Cultures were infected at an MOI 0.3. Cultures were fixed and labelled at times indicated 
to the left of the figure. Chlamydia are shown in green and host cells red. Isolates examined were C. pecorum 
IPTaLE, C. pecorum MarsBar and C. pecorum DBDeUG.
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JO146 treatment is most effective when maintained in the culture throughout the replicative 
and transition to infectious phase of the developmental cycle. In order to understand the 
chlamydial developmental cycle factors that impact on treatment efficacy, we conducted further in vitro exper-
iments varying the length of JO146 treatment. Firstly, we tested short exposures limited to the peak replicative 
phase, and secondly, extended exposures to ensure the compound is not simply slowing the developmental 
cycle. Previously, treatments of C. trachomatis D/UW-3/Cx showed JO146 to be most effective when maintained 
in the culture throughout the replicative and transition to infectious developmental cycle phase (elementary 
bodies)21.
We added JO146 to cultures of C. pecorum IPTaLE and C. pneumoniae LPCoLN at 16 h PI and subsequently 
removed it from the culture by extensive washing at 24 h PI. We determined Chlamydial viability at 44 h PI 
(C. pecorum IPTaLE) and 72 h PI (C. pneumoniae LPCoLN; Fig. 4) and found that JO146 was only slightly effec-
tive on C. pecorum IPTaLE when washed out 8 h after treatment (24 h PI) with only a 1-log reduction in viability. 
The compound had a greater effect on C. pneumoniae LPCoLN when washed out 8 h after treatment (24 h PI), 
with a 2-log reduction in viability. The ability of these isolates to recover after treatment with JO146 for 8 h 
demonstrates a need for the compound to be maintained in culture throughout the replicative phase and into the 
infectious phase of the developmental cycle.
To examine the long term stability of the drug, we determined if infectivity can be rescued by extended cultur-
ing after exposure to the drug. We added JO146 to cultures of C. pecorum IPTaLE and C. pneumoniae LPCoLN 
at 16 h PI and measured infectious progeny at 48, 68, and 88 h PI (C. pecorum IPTaLE) and 70, 90 and 110 h PI 
(C. pneumoniae LPCoLN; Fig. 5). JO146 treatment at 16 h PI was still effective for C. pecorum IPTaLE after 
extended culturing and was not notably different between the 48–88 h PI exposures. JO146 treatment at 16 h PI 
for C. pneumoniae LPCoLN however, was lethal for chlamydial infectivity, even after extended culturing.
JO146 treatment blocks chlamydial inclusion vacuole expansion. Using confocal microscopy, 
we monitored inclusion vacuole size and inclusion numbers after 150 μ M JO146 was added to McCoy B grown 
C. pecorum IPTaLE and HEp-2 grown C. pneumoniae LPCoLN cultures at 16 h PI. As shown in Fig. 6, C. pecorum 
IPTaLE and C. pneumoniae LPCoLN treated cultures did not increase in size compared to control (DMSO) 
cultures, and at 40 h PI, C. pecorum IPTaLE inclusions treated with 150 μ m JO146 were 62% smaller than the 
control while C. pneumoniae LPCoLN inclusions treated with 150 μ m JO146 at 50 h PI were 83% smaller than 
control (Fig. 6). In addition, the number of inclusions in the JO146 treated cultures was fewer than that of 
control for both isolates, suggesting treatment induces loss of inclusions from the cultures (Fig. 6).
In addition, we examined C. pecorum cultures by western blot for the HtrA protein compared to β -actin controls. 
Neither the JO146 treatment or DMSO control treatments had any impact on β -actin levels. However, there was 
less HtrA protein in the JO146 treatment compared to the DMSO controls 12 (28 h PI) and 26 hours (40 h PI) after 
the 16 h PI addition of JO146 (see Supplementary Fig. S2).
JO146 is not cytotoxic for koala peripheral blood mononuclear cells. Previous studies by our lab-
oratory demonstrated that JO146 had no detectable toxicity as measured by cell lysis or metabolic turnover in 
mouse or human cell lines21. To ensure this was also the case for koala cells, we treated fresh koala peripheral 
blood mononuclear cells (PBMCs) with 100 μ M JO146 or DMSO control and assayed cytotoxicity. Cell lysis 
was assessed using the lactate dehydrogenase assay and metabolic turnover was monitored using the MTS 
Isolate (Koala)δ
MICα (μ g/ml) 
Tetracycline
MCCβ (μ g/ml) 
Tetracycline
MICα (μ g/ml) 
Chloramphenicol
MCCβ (μ g/ml) 
Chloramphenicol
MCCβ (μ g/ml) 
JO146
C. pecorum IPTaLE (Ocular) 0.250γ 0.250 0.750 0.500 > 90
C. pecorum AWH1 (Ocular) 0.125 0.125 0.500 0.500 > 90
C. pecorum AWH7 (Ocular) 0.250 0.125 0.500 0.500 60
C. pecorum DBDeUG (Urogenital) 0.250 0.250 0.750 0.750 > 90
C. pecorum MarsBar (Urogenital) 0.250 0.250 1.000 0.750 > 90
C. pecorum AWH2 (Urogenital) 0.125 0.125 0.500 0.500 > 90
C. pecorum AWH4 (Urogenital) 0.250 0.250 1.000 1.000 > 90
C. pecorum PM11 (Urogenital) 0.250 0.125 1.000 0.500 > 90
C. pecorum PM15 (Urogenital) 0.125 0.125 0.500 0.500 60
C. pecorum IPA 0.250 0.250 1.000 1.000 > 9030
C. pneumoniae LPCoLN 0.250 0.125 1.000 0.750 60
C. trachomatis D/UW-3/Cx 0.500 0.500 1.000 1.000 > 9030
C. trachomatis L2-434/Bu 0.250 0.250 1.000 1.000 > 9030
Table 1. In vitro susceptibility testing of koala C. pecorum and C. pneumoniae isolates. α MIC is defined 
as the concentration of antibiotic one two-fold dilution more concentrated than the MICTP (where MICTP 
is defined as the concentration of antibiotic where 90% of inclusions or greater displayed altered size or 
morphology). β MCC is defined as the lowest concentration of antibiotic that produces no morphologically 
normal inclusions by one freeze-thaw passage in 96-well microtiter plates. γ MIC antibiotic range tested was 
0.008 μ g/ml–2.000 μ g/ml, and cultures were infected with no less than 10,000 IFU/well. δ C. pecorum infections 
were fixed at 30 h PI while C. pneumoniae were fixed at 68 h PI.
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incorporation assay. JO146 was not cytotoxic to koala PBMCs as evident by the lack of cell lysis compared to 
the control. Metabolic turnover was moderately reduced by approximately 20% for PBMCs treated with 100 μ M 
JO146 (Table 2).
JO146 is not cytotoxic for koala endometrial and conjunctival cells when cultured ex vivo. To 
determine if JO146 could be a potential therapeutic treatment for koala chlamydiosis, it is essential that the cyto-
toxicity of the compound be examined directly on koala epithelial cells. As no stable koala cell line currently 
exists for use in in vitro studies, we established primary cell lines for use in this study. We isolated koala primary 
endometrial and conjunctival cells from epithelium of the koala endometrium and conjunctiva, respectively. We 
assayed these primary epithelial cells for cytotoxicity after treatment with 100 μ M JO146 and DMSO controls and 
found that JO146 was not cytotoxic to koala primary endometrial cells as evident by the lack of cell lysis compared 
to control. Metabolic turnover was reduced by approximately 23% for koala primary endometrial cells treated with 
Figure 3. JO146 inhibition during mid-replicative phase of the Chlamydia developmental cycle. Infectious yield 
at 44 h PI (C. pecorum) and 72 h PI (C. pneumoniae) of isolates treated with JO146 at mid-replicative phase (MOI 
0.3). Error bars indicate the standard error of the mean obtained from experimental replicates (minimum of 3). The 
different koala Chlamydia isolates tested were (A) C. pecorum ocular isolates; C. pecorum IPTaLE, C. pecorum AWH1, 
and C. pecorum AWH7, (B) C. pecorum UGT isolates; C. pecorum DBDeUG, C. pecorum MarsBar, C. pecorum 
AWH2, C. pecorum AWH4, C. pecorum PM11, and C. pecorum PM15, and (C) C. pneumoniae The concentration of 
JO146 used is indicated by grey scale shading (legend to the right). The presence of # indicates when the treatment 
was lethal and no inclusion forming units were detected.
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100 μ M JO146 while only 10% reduction in metabolic activity was detected for the DMSO treated control (Table 2). 
Similarly for the koala primary conjunctival epithelial cells we observed no toxicity (no cell lysis), but metabolic 
turnover was reduced by approximately 4% (100 μ M JO146 and DMSO control was reduced by 1%) (Table 2).
Figure 4. Infectious progeny yield at completion of the chlamydial developmental cycle following 8 h 
treatment with JO146. Media, JO146 (50, 100, 150 μ M) and DMSO was added to C. pecorum IPTaLE and to 
C. pneumoniae LPCoLN cultured at an MOI of 0.3 in McCoy B and HEp-2 cells respectively, at 16 h PI and left 
for 8 h. All wells were then washed with pre-warmed media and further incubated. The cultures were harvested 
for subsequent measurement of infectious progeny at the completion of the developmental cycle (C. pecorum 
IPTaLE 44 h PI, C. pneumoniae LPCoLN 72 h PI). Error bars indicate the standard error of the mean obtained 
from triplicate infected wells.
Figure 5. Infectious yield after treatment with JO146 for extended time. Media, JO146 (50, 100, 150 μ M) and 
DMSO was added to (A) C. pecorum IPTaLE and to (B) C. pneumoniae LPCoLN cultured at an MOI of 0.3 in 
McCoy B and HEp-2 cells respectively, at 16 h PI. The cultures were harvested for subsequent measurement of 
infectious progeny at time points extending further than completion of their developmental cycle. Shown are 
mean IFU/ml with error bars indicating the standard error of the mean obtained from triplicate infected wells.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:31466 | DOI: 10.1038/srep31466
JO146 significantly reduced infection of koala primary epithelial cell lines with C. pecorum isolates. 
As a final test of the potential efficacy of JO146 in a relevant cellular infection we treated koala primary endome-
trial cells infected with C. pecorum IPTaLE, C. pecorum DBDeUG or C. pecorum MarsBar at an MOI (multiplicity 
of infection) of 0.5 or 1.0 with 100 μ M JO146 or DMSO control at 16 h PI. As readout of the infection we meas-
ured the percentage of cells infected with chlamydial inclusions 35 h PI. JO146 treatment resulted in a significant 
(p < 0.1) reduction in the percentage of cells with chlamydial inclusions at both MOIs tested and for all three 
isolates in primary ex vivo koala endometrial cell cultures (Fig. 7).
Discussion
This study presents the first stage of development of a new therapeutic for koala chlamydiosis. With an increas-
ingly limited availability of the front-line antibiotic commonly used to treat koala chlamydiosis, a new treatment 
Figure 6. Chlamydial inclusion vacuole size fails to progress over time in cell culture after treatment with 
150 μM JO146. (A) Cultures treated with 150 μ M JO146 or DMSO control at 16 h PI (MOI 0.3). Cultures were 
fixed and labelled at times indicated to the left and treatment conditions indicated are at the top. C. pecorum 
IPTaLE were cultured in McCoy B cells, C. pneumoniae LPCoLN in HEp-2 cells. Chlamydia are shown in green 
and host cells red. (B) Quantitative representation of the inclusion size of JO146 and DMSO control treatments 
at each time point. IFU/FOV = Average Inclusion Forming Units per Field of View ± SE (n = 18). (C) Average 
inclusion size ± SE where C. pecorum IPTaLE (n = 5), C. pneumoniae LPCoLN (n = 4).
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is urgently needed. We have demonstrated significant reduction (and in some cases, lethality) in infectious prog-
eny of Chlamydia from koala clinical cases of disease using both in in vivo and ex vivo cell cultures.
In vitro susceptibility patterns of antibiotics across chlamydial spp. and hosts appear uniform25–27, and indeed, 
our results for susceptibility of koala C. pecorum isolates appear consistent with activity at or below the range pre-
viously reported (1–2 μ g/ml)28. These results indicate that the plasma concentrations of chloramphenicol reached 
in the koala (reaching a peak plasma concentration of 3.02 μ g/ml on day 1 of treatment, and 4.82 μ g/ml by day 
1512) are sufficient for treatment. However, for koalas affected by severe chlamydial disease, antibiotics alone are 
not sufficient to cure the clinical symptoms12. In addition, production of the commonly used antibiotic chloram-
phenicol is limited. Although there is a potential commercial alternative treatment (Florfenicol), pharmacokinet-
ics, efficacy or safety studies for this drug in koala chlamydiosis has not been carried out28. Therefore, alternative 
treatment strategies are required that not only treat the disease, but also limit side effects given the unique biology 
of the koala.
Very little in vitro growth data is available for koala C. pecorum or any strains of this species. Prior to assessing 
the efficacy of our therapeutic agent, it was necessary to analyse the growth characteristics of ocular and urogen-
ital koala C. pecorum strains. Growth curves have previously demonstrated that human C. trachomatis ocular 
and genital strains have quite distinct kinetics, with the ocular strains generally considered to be slow growing 
strains29. We tested three koala C. pecorum strains from ocular and urogenital sites and found that there were 
differences in the observed growth kinetics. Specifically, the C. pecorum IPTaLE (ocular) isolate has a longer lag 
phase and lower overall yield of infectious progeny (EBs) compared to the others. Genetically, the three strains 
are > 98% identical with variances limited to two regions; the plasticity zone and an area encoding polymorphic 
membrane proteins, where SNPs were found to cause premature stop codons in six C. pecorum genes23. Expanded 
in vitro and genetic studies of additional clinical isolates will be required to establish whether genital and ocular 
koala C. pecorum strains share similar tropisms to their human C. trachomatis counterparts.
As a first step to evaluating the efficacy of our HtrA protease inhibitor JO146, we treated cultures during the 
replicative phase (estimated to be ~16 h PI) of the koala C. pecorum and C. pneumoniae developmental cycle. 
This treatment resulted in significant loss of infectious progeny for many koala C. pecorum isolates and lethality 
for two koala C. pecorum isolates and koala C. pneumoniae. Analysis of the chlamydial cell morphology during 
treatment supported this loss of infectious progeny, with inclusion size failing to progress (and in some cases 
diminishing) within the treated cultures. As previously shown by our laboratory, mid-replicative phase addition 
of JO146 is detrimental to many species of Chlamydia including C. trachomatis D, C. trachomatis L2, C. pecorum 
IPA, C. suis and C. caviae and in many host cell types21,30. Here we show that JO146 treatment of C. pecorum 
IPTaLE and C. pneumoniae LPCoLN was most effective when maintained in the culture throughout the replica-
tive and transition to infectious phase of the developmental cycle. This indicates that lead drug candidates will 
need to be optimized for tissue stability and bio-availability with overall extended half-life in vivo.
The removal of JO146 at 24 h PI (8 h after treatment) showed only a 1-log (C. pecorum IPTaLE) and 2.5-log 
(C. pneumoniae LPCoLN) reduction in infectious progeny. However, when the compound was maintained in the 
media throughout the replicative phase, a 3-log (C. pecorum IPTaLE) and complete loss (C. pneumoniae LPCoLN) 
of infectious progeny resulted. Importantly, with extended culture of C. pecorum IPTaLE (68 and 88 h PI), there 
was no rescue of infectious progeny and C. pneumoniae LPCoLN was similarly not able to recover at 90 and 110 h 
Koala PBMC LDH Assay - % cytotoxicity (n = 4)α
100 μM JO146§ DMSO
− 3.10 ± (3.41) 1.77 ± (3.02)
Koala PBMC MTS Assay - % proliferation (n = 4)α
100 μM JO146 DMSO
19.74 ± (3.041) 0.29 ± (1.23)
Koala Uterine Tissue LDH Assay - % cytotoxicity (n = 2)α
100 μM JO146§ DMSO§
− 3.96 ± (3.56) − 8.70 ± (6.17)
Koala Uterine Tissue MTS Assay - % proliferation (n = 2)α
100 μM JO146 DMSO
23.62 ± (0.20) 10.54 ± (1.52)
Koala Conjunctival Tissue LDH Assay - % cytotoxicity (n = 1)α
100 μM JO146§ DMSO
− 10.76 − 18.69
Koala Conjunctival Tissue MTS Assay - % proliferation (n = 1)α
100 μM JO146 DMSO
3.86 1.03
Table 2. Cytotoxicity and proliferation of cells treated with JO146. α Experiments were performed in 
triplicate and the results expressed as percentage cell death compared with untreated control cells by using 
the formula [1 − (mean absorbance of treated cells/mean absorbance of untreated cells)] * 100. Results are 
shown with SEM indicated in parenthesis. §Negative values indicate treated cultures had less cytotoxicity/more 
proliferation than control.
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PI. This result suggests a sustained effect of JO146 treatment and further supports its activity as being primarily 
bactericidal. This result could also suggest that the targets of JO146 (HtrA most likely but possible other serine 
proteases) are required for not only the replicative phase but also for the differentiation from reticulate bodies to 
the infectious elementary body form of Chlamydia.
Our previous research using JO146 supported that HtrA is essential for Chlamydia trachomatis serovar D dur-
ing the replicative phase of the developmental cycle22. These previous data suggested that Chlamydia HtrA func-
tions in critical protein maintenance and assembly; possibly for vital outer membrane virulence factors, based 
on some of our biochemical data31,32. This means that for Chlamydia at least HtrA is an essential virulence factor 
in addition to a well-known protein stress response function in many bacteria. However, this is not necessarily 
unexpected33, as HtrA is also an essential virulence factor for Legionella33.
A key finding of our study was the ability of JO146 to kill Chlamydia in koala primary ex vivo-cell cultures. 
There are no published reports of culturing Koala clinical isolates of Chlamydia in primary ex vivo koala cells and 
this method represents an important step forward in the context of an urgent need for new antibiotics. JO146 
significantly reduced the number of infected cells in cultures of C. pecorum isolates in koala primary endometrial 
cells. Unfortunately, the primary cultures were not able to be maintained and amplified sufficiently to passage the 
Chlamydia and measure the infectious progeny on repeat infections. Due to limits in the availability of freshly 
necropsied koala tissue, additional replicates of this experiment could also not be performed. Nevertheless, the 
results of this single ex vivo treatment of C. pecorum infections with JO146 are consistent with those obtained 
in vitro.
Importantly, cytotoxicity assays performed on freshly harvested koala PBMCs, endometrial and conjunctival 
cells confirmed overall low toxicity of JO146. We did observe a measurable reduction in proliferation induced by 
JO146 in all ex vivo primary cell cultures. However, it is hard to evaluate the implication of this result, given that 
the cells were not able to be maintained beyond three passages in all experiments attempted. This reduction may 
not occur in more stable primary ex vivo cells, which may or may not be relevant in vivo, hence further studies are 
required to assess the implications of this result.
Overall, our studies of JO146 have thus far shown that it can significantly reduce the infectious progeny of 
clinical isolates of koala chlamydial. The compound is lethal to many clinical isolates and induced several log 
reductions in the remaining isolates. The compound is non-cytotoxic to koala PBMCs, conjunctival, and endome-
trial primary ex vivo tissue, maintains stability in culture extending beyond the Chlamydia infectious cycle, and 
remained bactericidal throughout treatment. Although these results are promising, this compound in its current 
formulation, is not completely lethal to all isolates, therefore continued optimization will be required. Further 
studies are currently underway to generate more potent derivatives of JO146.
This is the first report of a protease inhibitor successfully being applied in vitro and ex vivo to treat koala C. 
pecorum and C. pneumoniae, and validates JO146 or other inhibitors derived from JO146 as possible options for 
treating koala chlamydiosis. Here we have provided the basis for future studies investigating the efficacy of JO146 
and further derivatives in vivo.
Methods
Ethics Statement. Koala Chlamydia pecorum strains isolated in this study were collected from koalas pre-
senting to Australia Zoo Wildlife Hospital and Port Macquarie Koala Hospital as a part of their routine veteri-
nary care and diagnosis. The use of these samples for Chlamydia culturing was considered by the University of 
the Sunshine Coast Animal Ethics Committee (USCAEC) and determined to be exempt from requiring fur-
ther approval (AN/E/14/01). Koala tissues for primary epithelial cell culture were collected from two koalas, 
Figure 7. JO146 efficacy on Chlamydia infected koala endometrial primary epithelial cells. Uterine primary 
epithelial cells were extracted from the uterus of a euthanized koala and infected with C. pecorum IPTaLE,  
C. pecorum DBDeUG, or C. pecorum MarsBar at an MOI of 0.5 or 1.0 and treated at 16 h PI with 100 μ M JO146 
or DMSO control. Shown is the mean percent infectivity (at 30 h PI, or 14 h after JO146 addition) with error 
bars indicating the standard error of the mean obtained from triplicate infected wells. The x axis indicates the 
different koala Chlamydia isolates and MOI.
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presenting to Australia Zoo Wildlife Hospital with injuries or disease. The animals were euthanized as a result of 
their condition and necropsy subsequently performed. The use of these koala tissues for this purpose was consid-
ered and also exempted from requiring further approval (AN/E/15/06).
Isolates used in this study. The ovine C. pecorum polyarthritis strain IPA (ATCC VR629), originally isolated 
from the joint fluid of a sheep in Iowa, USA34, C. trachomatis D (D/UW-3/Cx) and C. trachomatis L2 (L2-434/Bu), 
both obtained from the ATCC, were used as controls in this study. The isolates in Table 3 were all collected from 
captive and/or wild koalas located in Queensland and New South Wales, Australia. Swab samples were collected 
and stored in SPG transport media at point of care and frozen at − 80 °C. The koala C. pecorum isolates were prop-
agated in McCoy B cells and passaged no more than five times. All isolates have been confirmed by 16S RNA PCR 
and sequencing to be positive for C. pecorum8.
Chlamydia culture. C. pecorum and C. trachomatis isolates were routinely cultured in McCoy B cells on 
DMEM, 10% Fetal calf serum (FCS), 0.1 mg/ml streptomycin, and 0.05 mg/ml gentamycin. C. pneumoniae was 
routinely cultured in HEp-2 cells on DMEM, 10% FCS, 0.1 mg/ml streptomycin, and 0.05 mg/ml gentamycin. 
Inhibitor experiments were routinely conducted in 96-well plates seeded with 20,000 host cells per well 24 h prior 
to chlamydial infection. All strains were cultured in 37 °C incubators with 5% CO2 and, unless otherwise stated, 
all infections were routinely conducted at a Multiplicity of Infection (MOI) of 0.3. The Inclusion Forming Units 
(IFU) was determined from cultures harvested at the completion of the developmental cycle during which inhibi-
tor treatment was conducted (time of harvest is indicated on the figure). Briefly, JO146 and DMSO control (JO146 
solvent), at doses indicated on the graphs (always at a 1 in 1000 dilution factor), was added at 16 h post infection 
(PI) and left in the cultures until completion of the developmental cycle (or at time points indicated). Harvested 
cultures were lysed by vigorous pipetting and serially diluted onto fresh monolayers and fixed and stained at 30 h 
PI for enumeration of IFU/ml21. The compound JO146 was commercially sourced as previously described30.
Antimicrobial Susceptibility Testing of Koala Chlamydia isolates. Antimicrobial susceptibility test-
ing of koala C. pecorum and C. pneumoniae isolates in McCoy B and HEp-2 cell lines respectively, was performed 
as previously described35 with chloramphenicol and tetracycline on 96-well microtiter plates without passage 
(MIC) and by one passage (MCC). The inoculum size of infectious Chlamydia for all MIC and MCC compari-
sons was 10,000 IFU/well. The MIC was defined as the concentration of antibiotics one two-fold dilution more 
concentrated than the MICTP (where MICTP is defined as the concentration of antibiotics where 90% of inclusions 
or greater displayed altered size or morphology). The MCC is defined as the lowest concentration of drug that 
produces no morphologically normal inclusions by one freeze-thaw passage in 96-well microtiter plates.
Microscopy. C. pecorum and C. pneumoniae cultures were examined using immunofluorescence with a Leica 
SP5 Confocal microscope with a 63× oil objective. Coverslip cultures were washed with PBS and fixed with 100% 
methanol for 10 min. Cultures were stained with fluorescein isothiocyanate (FITC)-labelled Chlamydia-specific 
anti-lipopolysaccharide (anti-LPS) monoclonal antibody and host cells stained with Evan’s blue (Cell labs, 
Australia) and then mounted on slides in Prolong Gold (Invitrogen) prior to visualization.
Isolation of koala Peripheral Blood Mononuclear Cells. Koala Peripheral Blood Mononuclear Cells 
(PBMC’s) were isolated as previously described36. Briefly, the PBMC fraction was isolated by Ficoll-Paque density 
gradient centrifugation and washed twice with phosphate-buffered saline (PBS). The pellet was then resuspended 
in RPMI (10% FCS, 0.1 mg/ml streptomycin, and 0.05 mg/ml gentamycin) before seeding into 96-well plates 
12 h prior to use in cytotoxicity assays. All wells were stimulated with a final concentration of 100 μ g/ml Phorbol 
Myristate Acetate (PHA) at this time.
Isolation of koala primary epithelial cells. Tissue from the conjunctiva and endometrium were collected 
from two koala’s euthanized due to illness at Australia Zoo Wildlife Hospital. Harvested tissue was placed in HBSS 
media with 0.2% collagenase D and a homogenate prepared. The tissue was washed twice with HBSS and further 
Animal Code Symptoms of chlamydial disease Anatomical site Geographical location
C. pecorum IPTaLE 23 Conjunctivitis Eyes Ipswich, QLD
C. pecorum DBDeUG23 Cystitis UGT Deception bay, QLD
C. pecorum MarsBar23 Cystitis UGT Mt Cotton, QLD
C. pecorum AWH 1 Conjunctivitis Eyes Lake Somerset, QLD
C. pecorum AWH 2 UGT
C. pecorum AWH 4 Cystitis UGT Teddington, QLD
C. pecorum AWH 7 Conjunctivitis Eyes Noosa, QLD
C. pecorum PM 11 N/A UGT Port Macquarie region, NSW
C. pecorum PM15 N/A UGT
C. pneumonia LPCoLN10 Respiratory illness Nasopharynx Brisbane, QLD
Table 3.  Koala C. pecorum and C. pneumoniae isolates used in this study.
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treated with 2 U/ml DNase, with 10% FCS added to stop the DNase activity. The tissue was then spun and the 
pellet resuspended in red blood cell lysis buffer before being washed twice with complete keratinocyte-SFM and 
finally resuspended in complete keratinocyte-SFM, 10% fetal calf serum, 0.1 mg/ml streptomycin, 0.25 mg/ml 
Fungizone and 0.05 mg/ml gentamycin. Cells were passaged no more than two times before use in cytotoxic 
assays and JO146 efficacy assays.
Cytotoxicity and Proliferation Assays. Koala PBMC’s and primary conjunctival and endometrial cells 
were assayed for cytotoxicity after treatment with JO146 and DMSO controls using the lactate dehydrogenase 
assay for cell lysis (CytoTox 96® Non-Radioactive Cytotoxicity Assay, Promega). Metabolic turnover was mon-
itored using the MTS incorporation assay (CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay, 
Promega).
PBMCs were collected from anticoagulated blood from four different koalas. Epithelial cells were extracted 
from endometrial tissue of two koalas for primary culture. Conjunctival epithelial cells were extracted from con-
junctival tissue of one koala for primary culture. DMSO control was used at the same volume of DMSO as that 
added for 100 μ M JO146 treatments. PBMC’s were stimulated with a final concentration of 100 μ g/ml PHA at 12 h 
prior to treatment with JO146.
Statistical Analysis. All graphing and statistical analysis was conducted using the Prism GraphPad Software. 
ANOVA with multiple comparisons were conducted relative to the DMSO or cell control for statistical analysis, 
* * * * indicates p < 0.0001 or greater significance was identified.
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